Abbott's TEAM-HF Trial to Assess Early Use of HeartMate 3 LVAD in Heart Failure Patients
核心洞察
Abbott has initiated the TEAM-HF trial to evaluate the benefits of early HeartMate 3 (搜索) LVAD (搜索) implantation in advanced heart failure (搜索) patients, challenging current treatment guidelines.
The trial will enroll 850 patients across the US, comparing HeartMate 3 (搜索) LVAD (搜索) implantation versus continued medical therapy, with pulmonary artery pressure monitoring using Abbott's CardioMEMS HF system.
The primary goal is to determine if earlier LVAD (搜索) intervention improves patient outcomes, reduces hospitalizations, and enhances the quality of life for heart failure (搜索) patients.
Abbott has launched the TEAM-HF ( терапии с помощью HeartMate 3 (搜索)) trial, a prospective, randomized study designed to evaluate the clinical benefits of earlier intervention with the HeartMate 3 left ventricular assist device (LVAD (搜索)) in patients with worsening heart failure (搜索). This initiative challenges the current standard of care, which typically reserves LVAD implantation for patients with advanced heart failure who are heavily reliant on medication and have a poor prognosis.
The TEAM-HF trial plans to enroll up to 850 participants across the United States. Patients will be randomized to either receive a HeartMate 3 (搜索) LVAD (搜索) implant or continue with guideline-directed medical therapy. Pulmonary artery pressures (PAP) will be remotely monitored in both groups using Abbott’s CardioMEMS HF system, which is implanted via a catheter-based procedure. The trial will assess and compare the improvements in PAP between the two groups over a two-year period, with an option for long-term follow-up extending up to five years.
Objective Assessment for Timely Intervention
The trial's investigator highlighted that "the study aims to take the guesswork out of deciding when a patient has reached the ideal time for LVAD (搜索) implementation." By employing objective measures to accurately assess heart failure (搜索) progression, clinicians may be able to identify suitable candidates for LVAD therapy earlier in the course of their disease.
Potential Impact on Patient Outcomes
Keith Boettiger, vice president of Abbott’s heart failure (搜索) business, stated, "Our hope is that the TEAM-HF study will revolutionize care management for these patients and their families. Getting people on a heart pump more quickly could mean more time spent out of the hospital and with loved ones." The anticipated results of the TEAM-HF study could lead to improved survival rates and enhanced quality of life for patients with advanced heart failure.
Market Context and Future Projections
GlobalData predicts the cardiovascular medical device market will reach $86.5 billion by 2030, while the LVAD (搜索) market is projected to reach $2.24 billion by 2033. Abbott’s HeartMate 3 (搜索) is currently a market leader in this field. In August, the FDA expanded the label for the HeartMate 3 device to eliminate the need for aspirin use as part of routine patient management, potentially improving its adoption compared to other LVAD devices.